Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Jan 7, 2007; 13(1): 104-124
Published online Jan 7, 2007. doi: 10.3748/wjg.v13.i1.104
Published online Jan 7, 2007. doi: 10.3748/wjg.v13.i1.104
Antiviraldrug | Oral dose(mg/kgper day) | Treatmentduration(wk) | Follow upduration(wk) | Serum WHVDNA reduction(log) | Time to viralrecrudescence(wk) | Drug-associatedtoxicity | Other viral markers | Ref. |
Lamivudine | 1 | 24 | 24 | 1.5 | within 1-2 | none | WHV RI red. (3-fold) | [141] |
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
5 | 4 | 12 | 3.4 | within 1 | none | WHV RI red. (4-fold) | [21] | |
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
5 | 12 | 12 | 1.9 | within 1-2 | none | WHV RI red. (3-fold) | [157] | |
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
15 | 4 | 12 | 5.4 | within 1 | none | WHV RI red. (12-fold) | [21] | |
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
Adefovir | 5 | 12 | 6 | 1.7 | within 6 | none | [144] | |
15 | 12 | 6 | 2.5 | within 6 | none | [144] | ||
Entecavir | 0.02 | 12 | 12 | 7-81 | within 2-10 | none | WHV RI red. in individual animals to undetectable levels | [139] |
0.1 | 12 | 12 | 7-8 | within 6-10 | none | WHV RI red. in most animals to undetectable levels | [139] | |
Tenofovir | 5 | 4 | 12 | 1.5 | within 1-4 | none | no WHV RI red. | [147] |
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
15 | 4 | 12 | 1.2 | within 1-4 | none | no WHV RI red. | [147] | |
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
Emtricitabine | 3 | 4 | 12 | 1.4 | within 1-2 | none | WHV RI red. (3-fold) | [149] |
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
10 | 4 | 12 | 3.2 | within 1-2 | none | WHV RI red. (13-fold) | [149] | |
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
30 | 4 | 12 | 4.9 | within 1-2 | WHV RI red. (80-fold) | [149] | ||
no WHV RNA red. | ||||||||
no serum WHsAg red. | ||||||||
202 | 4 | 4 | 1.4 | within 1-2 | none | [148] | ||
302 | 4 | 4 | 1.8 | within 1-2 | none | WHV RI red. (2-fold) | [148] | |
Telbivudine | 10 | 4 | 8 | 8 | within 4-8 | none | serum WHsAg red. | [151-153] |
Valtorcitabine | 10 | 4 | 8 | 4-6 | within 1-8 | none | [151-153] | |
Clevudine | 3 | 4 | 12 | 9.2 | within 2-10 | none | WHV RI red. (28-fold) | [154] |
no WHV RNA red. | ||||||||
serum WHsAg red. (2-fold) | ||||||||
10 | 4 | 12 | 8.2 | within 8-123 | none | WHV RI red. (68-fold) | [154] | |
WHV RNA red. (2.7-fold) | ||||||||
serum WHsAg red. (4-fold) | ||||||||
WHV cccDNA red. (2-6-fold or to undetectable levels) |
- Citation: Menne S, Cote PJ. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 2007; 13(1): 104-124
- URL: https://www.wjgnet.com/1007-9327/full/v13/i1/104.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i1.104